| 2023-03-31 | +4.16 % |
|
| 2023-03-30 | -0.91 % |
- Novavax Inc.'s (NVAX) lack of success in the coronavirus vaccine market is a cause of concern for investors, as the company is projecting only about $900 million in sales next year, whereas, Moderna Inc. (MRNA) generated sales of $19.3 billion last year, and is projecting around $5 billion in 2023; thus, leading to a sell-off of Novavax's shares.
- Vertex Pharmaceuticals and Etsy are two no-brainer stocks to consider buying right now, with a portfolio of cystic fibrosis medicines and a growing active and habitual buyer cohorts, respectively, even though the stock market was down, including Moderna, which is working with Vertex on another cystic fibrosis drug candidate.
- Moderna (MRNA) stock was down 0.91% in yesterday's trading, while Pfizer's (PFE) stock has not grown significantly despite its record-setting sales due to COVID-19 treatment, as its market cap was already close to $200 billion in 2020 and its overall business is heading towards a transition phase with a decline expected in revenue because of the loss of patent-protected drugs, while Moderna's COVID-19 vaccine has helped it rise on investors' radar, making it an up-and-coming growth stock with a market cap of $57 billion.
|
| 2023-03-29 | +1.28 % |
|
| 2023-03-28 | -0.96 % |
|
| 2023-03-24 | +0.98 % |
|
| 2023-03-23 | +0.84 % |
|
| 2023-03-22 | -2.58 % |
|
| 2023-03-21 | -1.57 % |
|
| 2023-03-20 | +3 % |
|
| 2023-03-17 | -1.16 % |
|
| 2023-03-16 | +1.46 % |
|
| 2023-03-15 | -1.11 % |
|
| 2023-03-14 | +2.29 % |
|
| 2023-03-13 | +6.95 % |
|
| 2023-03-10 | +0.68 % |
- Moderna(MRNA) stock went up after the company announced plans to add 2,000 employees and expand its presence in the U.S. despite U.S. equities falling due to the collapse of Silicon Valley Bank and a slowdown in wage growth leading to speculation about the Fed moderating its interest rate hikes.
- Moderna's stock went up by 0.68% last night as the company works on potential products in its pipeline, including jabs for influenza, respiratory syncytial virus, cytomegalovirus, and personalized cancer vaccine in phase 2 trials in collaboration with Merck, with the potential to revolutionize treatment of cancers like melanoma.
- Moderna plans to hire 2,000 employees globally by 2023, open new offices on the US West Coast, and expand its Genomics unit in south San Francisco to scale up development of new products, which boosted its stock by 0.68% as it aims to diversify its offerings amid declining COVID vaccine sales.
- The article discusses a post hoc analysis of the ORAL Surveillance trial, which found that patients with rheumatoid arthritis (RA) and a history of atherosclerotic cardiovascular disease (ASCVD) had an increased risk of major adverse cardiovascular events (MACE) with tofacitinib versus tumor necrosis factor inhibitors (TNFi), but the risk was not identified in the wider tofacitinib RA clinical trial program, possibly due to a difference in the proportion of patients with a history of ASCVD between the two trials. As for why Moderna (MRNA) stock went up, the article does not mention any correlation with the stock market.
- Novavax's stock has fallen by 97% from its peak as demand for its COVID-19 vaccine falls, while costs rise and it questions its future, but it potentially has a quality vaccine and a combined coronavirus/flu candidate that could attract those who go for an annual flu shot, resulting in a rejuvenated company down the road, says analyst Adria Cimino, but until it shows results, it remains high risk as the company itself has raised doubts where it will be in a year. Moderna's (MRNA) stock went up by 0.68% last night.
|
| 2023-03-09 | -3.32 % |
- Moderna's stock price was down by 3.32% as demand for its only product, a coronavirus vaccine, appears to be in persistent decline, but with three new products set to launch within the next two years, it could be a smart long-term investment for those who have the patience to hold shares for at least five years or more and can avoid selling when the temptation to do so may be high.
- Autolus Therapeutics reported positive clinical trial results for its product candidate; however, Moderna's stock went down due to lower than expected earnings in the fourth quarter of 2022.
- Moderna's stock went down by 3.32% as vaccine demand is declining as we move closer to a post-pandemic situation, which means a significant drop in revenue for the company since the vaccine is the company's only commercialized product.
- Moderna (MRNA) shares fell by 3.32% last month due to the drugmaker's underwhelming Q4 earnings report, which showed a decrease in EPS of 68% compared to the previous year and missed Wall Street's forecast by 23%, reflecting the industry's adjustment period as investors and pharmaceutical companies overestimated the demand for COVID-19 treatments.
- The article discusses two businesses, Vertex Pharmaceuticals and Shopify, that have strong core businesses and promising growth potential, with Vertex Pharmaceuticals being in a robust position due to its approved drugs for cystic fibrosis, multiple prospective candidates, and a superior financial strength, while Shopify is continuing to record business wins due to its platform and core business model, growing revenue, and aggressive investments in the tools and solutions it offers to merchants, which is how merchants retain more customers and can induce merchants to stay with Shopify over a competitor's platform. The article does not discuss why Moderna (MRNA) stock specifically went down.
|
| 2023-03-08 | +0.73 % |
|
| 2023-03-07 | -2.07 % |
|
| 2023-03-06 | +0.58 % |
|
| 2023-03-03 | +3.87 % |
|
| 2023-03-02 | +1.62 % |
- Moderna (MRNA) stock went up 1.62% last night on the back of increased demand for COVID-19 vaccines, as hospitalizations and deaths due to the virus continue to rise in the US.
- The stock of biotech company Moderna (MRNA) rose by 1.62% last night, potentially due to the market's expectation of increasing demand for its mRNA nucleic acid from laboratory research, clinical trials, and medical product manufacturing, as the market for medicines made from nucleic acids is estimated to grow from $42.5 billion in 2021 to $128.1 billion by 2030, and Maravai Life Sciences (MRVI) will possibly make around $100 million from sales of Maravai's mRNA this year.
- Moderna (MRNA) stock went up by 1.62%, as investors became optimistic about the potential growth and revenue from post-pandemic vaccine sales, as the company aims to target the market for annual coronavirus boosters, which it compares to that of the flu vaccine, with Moderna predicting that around 30% of the US population will go for a coronavirus vaccine or booster this year.
- Moderna(MRNA) stock went up by 1.62%, and Novavax(NVAX) struggles to keep up as demand for pandemic protection declines, leading to short-sellers earning $2.7 billion, with its warning about staying in business deepening its losses.
- Shares of Novo Nordisk, a Danish drugmaker, have risen on hopes that its diabetes and obesity drugs could become the biggest-selling class of pharmaceuticals ever, with the newest weight-loss injectable drug, Wegovy, being the first drug for obesity approved by the FDA in years, leading some U.S. insurers to cover it, and is forecast to divide most of the market with Eli Lilly whose Mounjaro may win FDA approval for obesity this year.
|
| 2023-03-01 | -2.27 % |
|
| 2023-02-28 | +0.39 % |
|
| 2023-02-27 | -0.71 % |
|
| 2023-02-24 | -5.63 % |
|
| 2023-02-23 | -6.7 % |
|
| 2023-02-22 | -1.2 % |
|
| 2023-02-21 | -3.91 % |
|
| 2023-02-17 | -3.31 % |
|
| 2023-02-16 | -2.8 % |
|
| 2023-02-15 | +0.95 % |
|
| 2023-02-14 | +2.41 % |
|
| 2023-02-13 | +1.3 % |
|
| 2023-02-10 | +2.92 % |
|
| 2023-02-08 | -3.93 % |
|
| 2023-02-07 | +0.46 % |
|
| 2023-02-06 | -1.72 % |
|
| 2023-02-03 | -1.76 % |
|
| 2023-02-02 | +1.18 % |
|
| 2023-02-01 | -1 % |
|
| 2023-01-31 | -2.66 % |
|
| 2023-01-30 | -4.48 % |
|
| 2023-01-27 | -2.01 % |
|
| 2023-01-25 | -1.88 % |
|
| 2023-01-24 | -0.09 % |
|
| 2023-01-23 | +1.53 % |
|
| 2023-01-20 | +1.89 % |
|
| 2023-01-19 | -3.37 % |
|
| 2023-01-18 | +3.32 % |
|
| 2023-01-17 | -0.68 % |
|
| 2023-01-13 | +2.1 % |
|
| 2023-01-12 | +0.76 % |
|
| 2023-01-11 | -1.59 % |
|
| 2023-01-10 | +3.1 % |
|
| 2023-01-09 | +2 % |
|
| 2023-01-06 | +3.94 % |
|
| 2023-01-05 | -2.17 % |
|
| 2023-01-04 | -0.91 % |
|
| 2023-01-03 | -0.35 % |
|
| 2022-12-30 | +0.42 % |
|
| 2022-12-27 | -9.5 % |
|
| 2022-12-22 | -0.81 % |
|
| 2022-12-21 | +4.41 % |
|
| 2022-12-20 | +5.94 % |
|
| 2022-12-15 | -0.81 % |
|
| 2022-12-14 | +5.78 % |
|
| 2022-12-13 | +19.63 % |
|
| 2022-12-08 | +3.18 % |
|
| 2022-12-06 | -1.36 % |
|
| 2022-12-02 | +0.48 % |
|
| 2022-12-01 | +3.17 % |
|
| 2022-11-29 | -1.27 % |
|
| 2022-11-25 | -0.23 % |
|
| 2022-11-22 | +1.61 % |
|
| 2022-11-14 | +4.57 % |
|
| 2022-11-10 | +3.28 % |
|
| 2022-11-09 | -0.85 % |
|
| 2022-11-03 | -0.75 % |
|
| 2022-10-21 | +8.4 % |
|
| 2022-10-18 | -3.71 % |
|
| 2022-10-14 | -0.53 % |
|
| 2022-10-13 | +3.06 % |
|
| 2022-10-12 | +8.28 % |
|
| 2022-10-10 | +3.44 % |
|
| 2022-10-05 | -0.04 % |
|
